Introduction:
Leading pharma company has secured exclusive licensing rights to develop MET-X in India, a novel MBL inhibitor targeting drug-resistant Gram-negative infections. This move aims to combat rising antimicrobial resistance, with clinical trials set to begin under global regulatory standards.
Share price movement of Venus Remedies:
On February 25, 2025, Venus Remedies Ltd. opened at ₹303.50, down 1.16% from its previous close of ₹307.05. The stock reached a high of ₹320.00 (4.22%) and a low of ₹303.50. By 11:46 AM, it traded at ₹316.15, a 2.96% increase, with a market cap of ₹422.60 crore.
Venus Remedies Secures Exclusive Rights to Develop MET-X in India:
Venus Remedies Ltd., a leading pharmaceutical company, has signed an exclusive licensing agreement with Infex Therapeutics to develop MET-X in India. MET-X, a novel MBL inhibitor, has shown best-in-class performance in preclinical studies against drug-resistant Gram-negative infections.
India faces a high prevalence of meropenem-resistant pathogens, with resistance rates reaching up to 87%. Under the agreement, Venus Remedies will lead clinical trials, regulatory approvals, and commercialization of MET-X, integrating it with meropenem to combat antimicrobial resistance in critical care settings.
The company will commence Phase I trials in India, adhering to global regulatory standards, including FDA and EMA guidelines. This collaboration strengthens Venus Remedies’ leadership in antibiotic R&D, with potential future expansions to develop additional MET-X-based treatments targeting multidrug-resistant bacterial infections.
Recent news on Venus Remedies:
As of February 05, 2025, Venus Remedies Ltd. hit a 20% upper circuit at ₹348.60 after reporting a 186.13% surge in net profit to ₹19.60 crore, driven by a 23.31% revenue growth in Q3 FY25 over Q3 FY24.
Ace investor holding in Venus Remedies:
K.B. Shekar
K.B. Shekar holds a 1.97% stake in Venus Remedies Ltd., owning 262,680 shares valued at ₹8.3 crore. This investment highlights confidence in the company’s growth prospects, following its strong financial performance and strategic advancements in the pharmaceutical sector.
Stock performance of Venus Remedies for Period of 1 week, 6 months and 1 year:
Venus Remedies Ltd. delivered a modest 0.34% gain over the past week but faced a 11.8% decline over six months and an 11.2% drop over the past year, reflecting market volatility despite the company’s strong financial and strategic advancements.
Also Read: Renewable energy stock jumps after sells 100% stake in its US subsidiary for ₹350 Cr
Shareholding pattern of Venus Remedies:
Particulars | Dec 2024 | Sep 2024 | Jun 2024 |
Promoter | 41.80% | 41.80% | 41.80% |
FII | 1% | 1% | 1.10% |
DII | 0% | 0.20% | 0.20% |
Public | 57.10% | 56.90% | 57.00% |
About Venus Remedies:
Venus Remedies Ltd. (NSE: VENUSREM) is a research-driven pharmaceutical company specializing in injectables. A leading meropenem manufacturer, it holds 135+ patents and 1,040+ global marketing authorizations, offering diverse formulations across antibiotics, oncology, neurology, pain management, and antimicrobial resistance therapies.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.